October 21, 2024
2 min watch
Save
VIDEO: Ocular Therapeutix shares update on phase 3 Axpaxli studies
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the next steps for the phase 3 SOL-1 and SOL-R studies.
The studies, which are investigating Axpaxli (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration, are moving toward completion of randomization for SOL-1 and enrollment for SOL-R.
“We’ve designed these two studies not only to be complementary but to be strategic in a way that all the questions that I believe the investigators as well as the physicians will have will be answered,” Dugel said.
Reference:
- Ocular Therapeutix announces accelerated timelines for SOL-1 registrational trial of Axpaxli in wet AMD. https://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-announces-accelerated-timelines-sol-1. Published Oct. 15, 2024. Accessed Oct. 21, 2024.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dugel reports being executive chairman, president and CEO of Ocular Therapeutix.
Read more about